Hypermetabolic Hurthle Cell Adenoma on 18F-FDG PET/CT

The hypermetabolic giant: 18F-FDG avid giant cell tumor identified on PET-CT.

An 87 year-old white female presented with a two-year history of intermittent discomfort in her left foot. PET-CT identified intense18F-fluorodeoxyglucose (FDG) uptake corresponding to the lesion. Histology of a fine needle aspiration and open biopsy were consistent with a benign giant cell tumor (GCT) of the bone. GCT of bone is an uncommon primary tumor typically presenting as a benign solita...

FDG PETCT in colorectal cancer

Colorectal cancer represents the second most common malignancy worldwide, with approximately one million newly diagnosed cases each year, and is the fourth leading cause of cancer mortality. This article provides an overview of the role of FDG (fluorodeoxyglucose) PET (positron emission tomography) CT (computed tomography) for assessment in patients with colorectal cancer. A summary of key lear...

Scar sarcoidosis on 18F-FDG PET/CT

18F-labeled fluoro-2-deoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) is an important imaging modality in the clinical workup of patients with chronic inflammatory disorders which present quite often with a fever of unknown origin. Sarcoidosis is a multisystem chronic inflammatory disorder with a wide clinical spectrum that can involve different organs. The diagno...

Unexpected focal hypermetabolic activity in the breast: significance in patients undergoing 18F-FDG PET/CT.

OBJECTIVE We describe the significance of detecting focal areas of hypermetabolism in the breast in patients undergoing PET/CT for reasons other than for breast cancer detection or staging. CONCLUSION When evaluated, almost all of the abnormal foci detected in the breast subsequently proved to be breast carcinoma, specifically infiltrating ductal carcinoma.

Reduced-dose [F]-FDG PETCT scanning with current generation PETCT systems